Author: Allarity Therapeutics, Inc.

Posted Date:

March 31, 2026

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics, Inc.

March 31, 2026
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics, Inc.

March 6, 2026
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Allarity Therapeutics, Inc.

February 18, 2026
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Allarity Therapeutics, Inc.

February 3, 2026